Products
Pamvatamig Biosimilar Bispecific Antibody (MET × EGFR) for Research
Cat No.: GMP-Bios-INN-1327
Anti-MET/HGFR therapeutic antibody (Pre-made Pamvatamig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pamvatamig (development code MCLA129) is a bispecific antibody targeting MET and EGFR. It is developed by Merus and Betta Pharmaceuticals. It is in Phase I/II clinical development for solid tumors.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1327-1mg | 1mg | |
| GMP-Bios-INN-1327-10mg | 10mg | |
| GMP-Bios-INN-1327-100mg | 100mg | |
| GMP-Bios-INN-1327-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Pamvatamig biosimilar, Bispecific mAb, Anti-MET/HGFR;EGFR/ERBB1/HER1 Antibody: Anti-c-Met/MET/Hepatocyte growth factor receptor/HGF receptor therapeutic antibody |
| INN Name | Pamvatamig |
| Target | MET/HGFR;EGFR/ERBB1/HER1 |
| Format | Bispecific mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Merus;Betta Pharmaceuticals Co Ltd |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Non-small cell lung cancer; Solid tumours |
| Production | na |
| Development Tech | na |
